| Aethlon Medical is a medical technology company. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The U.S. Food and Drug Administration has designated the Hemopurifier as a Breakthrough Device for two independent indications: the treatment of individuals with metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and the treatment of life-threatening viruses that are not addressed with approved therapies. We show 26 historical shares outstanding datapoints in our coverage of AEMD's shares outstanding history.|
Understanding the changing numbers of AEMD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AEMD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AEMD by allowing them to research AEMD shares outstanding history
as well as any other stock in our coverage universe.